The fund typically invests in rounds with 5-6 participants and has been involved in deals ranging from $10 million to $50 million. It has a track record of committing exits more frequently than other organizations. While the fund does not have a specific preference for founders, it tends to invest in startups in the pharmaceutical and biotechnology industries. The fund has invested in companies such as AM Pharma and NovaGo Therapeutics and typically targets startups that are 11-15 years old. Additionally, the fund manages a total of $170 million and focuses on investing in pre-clinical and clinical-stage drug developers.